Bimekizumab for The Treatment of Psoriasis

References

• Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133(2), 377–385 (2013).
   PubMed Web of Science ®Google Scholar
• Langley RGB. Psoriasis: epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 64(Suppl. 2), ii18–ii23 (2005).
   PubMed Web of Science ®Google Scholar
• Queiro R, Tejon P, Alonso S, Coto P. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology 53(7), 1178–1185 (2014).
   PubMed Web of Science ®Google Scholar
• Larsabal M, Ly S, Sbidian E et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br. J. Dermatol. 180(3), 647–656 (2019).
   PubMed Web of Science ®Google Scholar
• Eder L, Widdifield J, Rosen CF et al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthr. Care Res. 71(8), 1084–1091 (2019).
   Web of Science ®Google Scholar
• Huffmeier U, Lascorz J, Becker T et al. Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. J. Med. Genet. 46(11), 736–744 (2009).
   PubMed Web of Science ®Google Scholar
• O’rielly DD, Jani M, Rahman P, Elder JT. The genetics of psoriasis and psoriatic arthritis. J. Rheumatol. 95, 46–50 (2019).
   Google Scholar
• Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Quality Life Outcom. 4(1), 35 (2006).
   PubMedGoogle Scholar
• Strober B, Tada Y, Mrowietz U et al. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br. J. Dermatol. doi:10.1093/bjd/ljad035 (2023).
   Web of Science ®Google Scholar
• Cole S, Manghera A, Burns L et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J. Allergy Clin. Immunol. 152(3), 783–798 (2023).
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19), 1945–1960 (2020).
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Günther S, Moderer M et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol. 119(5), 1096–1102 (2002).
   PubMed Web of Science ®Google Scholar
• Van Der Fits L, Van Der Wel LI, Laman JD, Prens EP, Verschuren MCM. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-α sensitivity is unaltered. J. Invest. Dermatol. 122(1), 51–60 (2004).
   PubMed Web of Science ®Google Scholar
• Mckenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27(1), 17–23 (2006).
   PubMed Web of Science ®Google Scholar
• Wang F, Lee E, Lowes MA et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J. Invest. Dermatol. 126(7), 1590–1599 (2006).
   PubMed Web of Science ®Google Scholar
• Hänsel A, Günther C, Ingwersen J et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T 17/T 1 T-cell responses. J. Allergy Clin. Immunol. 127(3), 787–794.e789 (2011).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Wortmann S, Kaufmann R, Mielke V, Sterry W. A subset of macrophages located along the basement membrane (“lining cells”) is a characteristic histopathological feature of psoriasis. Am. J. Dermatopathol. 17(2), 139–144 (1995).
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Matheson RT et al. Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp. Dermatol. 24(7), 529–535 (2015).
   PubMed Web of Science ®Google Scholar
• Glowacka E, Lewkowicz P, Rotsztejn H, Zalewska A. IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. Adv Med Sci 55(2), 254–260 (2010).
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PC, Lammers AM. Intraepidermal accumulation of polymorphonuclear leukocytes in chronic stable plaque psoriasis. Dermatologica 174(5), 224–227 (1987).
   PubMedGoogle Scholar
• Nikaein A, Phillips C, Gilbert SC et al. Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J. Invest. Dermatol. 96(1), 3–9 (1991).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Warren RB et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from Phase II and Phase III Randomized Clinical Trials. JAMA Dermatol 158(7), 735–744 (2022).
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 34(2), 149–162 (2011).
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129(6), 1339–1350 (2009).
   PubMed Web of Science ®Google Scholar
• Hollox EJ, Huffmeier U, Zeeuwen PLJM et al. Psoriasis is associated with increased β-defensin genomic copy number. Nat. Genet. 40(1), 23–25 (2008).
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Claffey KP et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. 180(3), 1141–1146 (1994).
   PubMed Web of Science ®Google Scholar
• Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10(3), 149–166 (2007).
   PubMedGoogle Scholar
• Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ et al. Target molecules for future hidradenitis suppurativa treatment. Exp. Dermatol. 30(S1), 8–17 (2021).
   PubMedGoogle Scholar
• Merola JF, Landewé R, Mcinnes IB et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, Phase III trial (BE COMPLETE). The Lancet 401(10370), 38–48 (2023).
   PubMed Web of Science ®Google Scholar
• Coates LC, Mcinnes IB, Merola JF et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a Phase IIb randomized controlled trial and its open-label. Arthr. Rheumatol. 74(12), 1959–1970 (2022).
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Deodhar A, Baraliakos X et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel Phase III randomised controlled trials. Ann. Rheum. Dis. doi: 10.1136/ard-2022-223595 (2023).
   Google Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann. Rheum. Dis. 77(2), 175–187 (2018).
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela Snr E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis Targets Ther. 12, 127–137 (2022).
   PubMed Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br. J. Clin. Pharmacol. 83(5), 991–1001 (2017).
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therap. Advan. Chronic Dis. 12, 204062232110378 (2021).
   Web of Science ®Google Scholar
• Oliver R, Krueger JG, Glatt S et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a Phase IIa, randomized, double-blind multicentre study. Br. J. Dermatol. 186(4), 652–663 (2022).
   PubMed Web of Science ®Google Scholar
• Koppu S, Singh R, Kaur K, Feldman SR. Review of bimekizumab in the treatment of psoriasis. Hum. Vacc. Immunotherap. 18(6) (2022).
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled Phase IIb trial. J. Am. Acad. Dermatol. 79(2), 277–286.e210 (2018).
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Merola JF et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, Phase IIb extension study. J. Am. Acad. Dermatol. 83(5), 1367–1374 (2020).
   PubMed Web of Science ®Google Scholar
• Australian regulatory agency. Bimekizumab for plaque psoriasis. Aust. Prescr. 45(4), 132–133 (2022).
   PubMedGoogle Scholar
• Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics 15, 247–253 (2021).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal Phase III trial. Lancet 397(10273), 475–486 (2021).
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J et al. Bimekizumab versus adalimumab in plaque psoriasis. N. Engl. J. Med. 385(2), 130–141 (2021).
   PubMed Web of Science ®Google Scholar
• Thaci D, Vender R, De Rie MA et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br. J. Dermatol. 188(1), 22–31 (2023).
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled Phase III trial. Lancet 397(10273), 487–498 (2021).
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis — results of two Phase III trials. N. Engl. J. Med. 371(4), 326–338 (2014).
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M et al. Bimekizumab versus secukinumab in plaque psoriasis. N. Engl. J. Med. 385(2), 142–152 (2021).
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Warren RB, Strober B et al. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from Phase III/IIIb trials. Br. J. Dermatol. 188(3), 330–340 (2023).
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Narcisi A, Ibba L et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis). Front. Med. 10, (2023).
   Web of Science ®Google Scholar
• Bagel J, Tatla D, Hellot S et al. Bimekizumab self-injection devices: two multicenter, randomized, open-label studies on self-administration by patients with psoriasis. J. Drugs Dermatol. 21(2), 162–171 (2022).
   PubMed Web of Science ®Google Scholar